Aclaris Therapeutics has said it will cut 46% of its workforce after deciding to discontinue the development of lead drug zunsemetinib (ATI-450) for immuno-inflammatory in
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl